The following is a summary of “Longitudinal Links between Changes in Body Composition and Liver Disease Severity in Children ...

Cannabinoids used for medical purposes in children and adolescents come with a risk of adverse events, a systematic review ...

In hepatology, the term overlap syndrome describes variant forms of the major hepatobiliary autoimmune diseases, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing ...

The FDA has updated the prescribing information for Veozah (fezolinetant) to include a warning regarding the risk of serious liver injury.

Probiotic, prebiotic, and symbiotic supplements decrease liver enzymes, inflammatory cytokines, and lipid profiles among adults with MASLD.

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

GLP-1 receptor agonist use was associated with a reduced risk of progressing to cirrhosis and related complications in ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Overall survival data were immature at the final iDFS analysis. Adverse events reported with the combination included decreases in lymphocytes, leukocytes, neutrophils, hemoglobin, and platelets.

The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.